P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials

Sotomi, Yohei; Matsuoka, Yuki; Hikoso, Shungo; Nakatani, Daisaku; Okada, Katsuki; Dohi, Tomoharu; Kida, Hirota; Oeun, Bolrathanak; Sunaga, Akihiro; Sato, Taiki; Kitamura, Tetsuhisa; Sakata, Yasushi

doi:https://doi.org/10.1038/s41598-023-39213-3

P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials

Sotomi, Yohei; Matsuoka, Yuki; Hikoso, Shungo et al.

Scientific Reports, 2023, 13(1), 12608

Number of Access:117（2025-04-30 13:07 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/94602

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
SciRep_13_1_12608	pdf	None	3.89 MB	82	2024.03.04

Creative Commons : Attribution

Item Information

Output File Export EndNote Basic Export Mendeley

Title	P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
Creator	CreatorName Sotomi, Yohei
	CreatorName Matsuoka, Yuki
	NRID 1000030423164 1000030423164 researchmap permalink hikoso_osakauniv hikoso_osakauniv CreatorName Hikoso, Shungo
	NRID 1000060444535 1000060444535 researchmap permalink dsyma dsyma Scopus Author ID 6603545219 6603545219 CreatorName Nakatani, Daisaku
	NRID 1000020776489 1000020776489 researchmap permalink katsuki_okada katsuki_okada Scopus Author ID 13613369100 13613369100 CreatorName Okada, Katsuki
	NRID 1000090838137 1000090838137 researchmap permalink dohi_1230 dohi_1230 Scopus Author ID 35071263000 35071263000 CreatorName Dohi, Tomoharu
	CreatorName Kida, Hirota
	CreatorName Oeun, Bolrathanak
	NRID 1000010812258 1000010812258 researchmap permalink 10812258 10812258 CreatorName Sunaga, Akihiro
	CreatorName Sato, Taiki
	NRID 1000030639810 1000030639810 ORCID 0000-0003-0107-0580 0000-0003-0107-0580 researchmap permalink Kitamura_T Kitamura_T Scopus Author ID 22234282700 22234282700 CreatorName Kitamura, Tetsuhisa
	NRID 1000000397671 1000000397671 ORCID 0000-0002-5618-4721 0000-0002-5618-4721 researchmap permalink C4589 C4589 Scopus Author ID 35395964700 35395964700 CreatorName Sakata, Yasushi
Description	Sotomi Y., Matsuoka Y., Hikoso S., et al. P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Scientific Reports 13, 12608 (2023); https://doi.org/10.1038/s41598-023-39213-3.
Abstract	It remains unknown whether the recent trend of short dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy can simply be applied to patients undergoing complex percutaneous coronary intervention (PCI). We performed a systematic review and meta-analysis to evaluate P2Y12 inhibitor monotherapy vs. conventional DAPT in patients undergoing complex PCI and non-complex PCI (PROSPERO: CRD42022335723). Primary endpoint was the 1-year Net Adverse Clinical Event (NACE). Among 5,323 screened studies, six randomized trials fulfilled the eligibility criteria. A total of 10,588 complex PCI patients (5,269 vs. 5,319 patients) and 25,618 non-complex PCI patients (12,820 vs 12,798 patients) were randomly assigned to P2Y12 inhibitor monotherapy vs. conventional DAPT. In complex PCI patients, P2Y12 inhibitor monotherapy was associated with a lower risk of NACE than conventional DAPT [Odds ratio (OR) 0.76, 95% confidence interval (CI) 0.63–0.91, P = 0.003], whereas in non-complex PCI patients, P2Y12 inhibitor monotherapy was associated with a trend toward lowering the risk of NACE (OR 0.86, 95% CI 0.72–1.02, P = 0.09). This meta-analysis across randomized trials demonstrated that a strategy of short DAPT followed by P2Y12 inhibitor monotherapy reduces the risk of 1-year NACE in patients undergoing complex PCI.
Publisher	Nature Research
Source Title	Scientific Reports
Volume (Issue)	13(1)
Page	12608
Date of Issued	2023-08-03
Language	English
Handle URL	https://hdl.handle.net/11094/94602
eISSN	20452322
Relation.isIdenticalTo	DOI (Publisher Version) https://doi.org/10.1038/s41598-023-39213-3
Access Rights	open access
CopyRight	This article is licensed under a Creative Commons Attribution 4.0 International License.
oaire:version	Version of Record
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	Scientific Reports. 2023, 13(1), p. 12608
DC.title	P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
DC.creator	Sotomi, Yohei
	Matsuoka, Yuki
	Hikoso, Shungo
	Nakatani, Daisaku
	Okada, Katsuki
	Dohi, Tomoharu
	Kida, Hirota
	Oeun, Bolrathanak
	Sunaga, Akihiro
	Sato, Taiki
	Kitamura, Tetsuhisa
	Sakata, Yasushi
DC.publisher	Nature Research
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2023-08-03
DC.identifier	https://doi.org/10.1038/s41598-023-39213-3
DC.description	Sotomi Y., Matsuoka Y., Hikoso S., et al. P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Scientific Reports 13, 12608 (2023); https://doi.org/10.1038/s41598-023-39213-3.
DCTERMS.abstract	It remains unknown whether the recent trend of short dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy can simply be applied to patients undergoing complex percutaneous coronary intervention (PCI). We performed a systematic review and meta-analysis to evaluate P2Y12 inhibitor monotherapy vs. conventional DAPT in patients undergoing complex PCI and non-complex PCI (PROSPERO: CRD42022335723). Primary endpoint was the 1-year Net Adverse Clinical Event (NACE). Among 5,323 screened studies, six randomized trials fulfilled the eligibility criteria. A total of 10,588 complex PCI patients (5,269 vs. 5,319 patients) and 25,618 non-complex PCI patients (12,820 vs 12,798 patients) were randomly assigned to P2Y12 inhibitor monotherapy vs. conventional DAPT. In complex PCI patients, P2Y12 inhibitor monotherapy was associated with a lower risk of NACE than conventional DAPT [Odds ratio (OR) 0.76, 95% confidence interval (CI) 0.63–0.91, P = 0.003], whereas in non-complex PCI patients, P2Y12 inhibitor monotherapy was associated with a trend toward lowering the risk of NACE (OR 0.86, 95% CI 0.72–1.02, P = 0.09). This meta-analysis across randomized trials demonstrated that a strategy of short DAPT followed by P2Y12 inhibitor monotherapy reduces the risk of 1-year NACE in patients undergoing complex PCI.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	94602
citation_title	P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
citation_author	Sotomi, Yohei
	Matsuoka, Yuki
	Hikoso, Shungo
	Nakatani, Daisaku
	Okada, Katsuki
	Dohi, Tomoharu
	Kida, Hirota
	Oeun, Bolrathanak
	Sunaga, Akihiro
	Sato, Taiki
	Kitamura, Tetsuhisa
	Sakata, Yasushi
citation_publisher	Nature Research
citation_language	English
citation_date	2023-08-03
citation_journal_title	Scientific Reports
citation_volume	13
citation_issue	1
citation_firstpage	12608
citation_doi	https://doi.org/10.1038/s41598-023-39213-3
citation_public_url	https://hdl.handle.net/11094/94602

P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials

Link to primary information

Item Information

Show details